HARVARD BIOSCIENCE INC(HBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,621 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
HBIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for HARVARD BIOSCIENCE INC (HBIO), a Technology sector company. 13F Pro's AI-powered ranking engine scores HBIO at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,621 of 2,962 stocks — the bottom half of the AI-ranked universe. HBIO scores in the top quartile across institutional flow (99.4). Areas of concern include revenue growth (10.5) and revenue scale (13.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HARVARD BIOSCIENCE INC reports quarterly revenue of $22.7M, net income of $-2.9M, an operating margin of -4.3%. Top institutional holders of HBIO by reported 13-F value include WEBER CAPITAL MANAGEMENT, Meros Investment Management, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. HBIO trades on the Nasdaq exchange and files with the SEC under CIK 1123494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARVARD BIOSCIENCE INC directly from SEC EDGAR. HARVARD BIOSCIENCE INC's 13F Pro composite quality score has ranged between 14 and 33 since 2021, currently 26.5 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$22.7M
Net Income
Q2 2026
$-2.9M
Free Cash Flow
Q2 2026
$-363.0K
Operating Margin
Q2 2026
-4.3%
ROIC
Q2 2026
-8.9%
D/E Ratio
Q2 2026
4.94
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-8.1% YoYNet Income
-357.1% YoYOperating Income
-682.2% YoYEPS (Diluted)
-357.1% YoYTotal Assets
-36.8% YoYTotal Debt
-51.5% YoYOp. Cash Flow
+367.3% YoYFree Cash Flow
+554.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $86.5M -8.1% | $94.1M -16.1% | $112.3M -1.0% | $113.3M -4.7% | $118.9M +16.5% | $102.1M |
| Net Income | $-56.7M -357.1% | $-12.4M -263.3% | $-3.4M +64.1% | $-9.5M -3204.2% | $-288.0K +96.3% | $-7.8M |
| Operating Income | $-48.6M -682.2% | $-6.2M -427.9% | $1.9M +127.3% | $-6.9M -435.6% | $2.1M +834.8% | $221.0K |
| EPS (Diluted) | $-1.28 -357.1% | $-0.28 -250.0% | $-0.08 +65.2% | $-0.23 | — | — |
| Total Assets | $80.1M -36.8% | $126.6M -7.8% | $137.4M -5.5% | $145.4M -10.5% | $162.3M +3.9% | $156.3M |
| Total Debt | $35.9M -51.5% | $73.9M +71.5% | $43.1M -15.4% | $50.9M -1.8% | $51.8M +3.7% | $50.0M |
| Operating Cash Flow | $6.7M +367.3% | $1.4M -89.7% | $14.0M +1117.7% | $1.2M -8.7% | $1.3M -86.5% | $9.3M |
| Free Cash Flow | $5.5M +554.4% | $-1.2M -109.8% | $12.2M +2894.5% | $-438.0K -753.7% | $67.0K -99.2% | $8.2M |
Get alerted when HBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for HARVARD BIOSCIENCE INC including:
Top Institutional Holders of HBIO
WEBER CAPITAL MANAGEMENT LLC /ADV
$1.9M310,861 shMeros Investment Management, LP
$1.1M182,992 shACADIAN ASSET MANAGEMENT LLC
$1.1M179,614 shVANGUARD CAPITAL MANAGEMENT LLC
$1.0M169,625 shNANO CAP NEW MILLENNIUM GROWTH FUND L P
$880.0K143,082 shCORSAIR CAPITAL MANAGEMENT, L.P.
$755.3K122,810 shTWO SIGMA INVESTMENTS, LP
$704.5K114,545 shRENAISSANCE TECHNOLOGIES LLC
$610.9K99,327 shBlackRock, Inc.
$380.3K61,834 shGEODE CAPITAL MANAGEMENT, LLC
$292.5K47,555 sh
| Fund | Value | Shares |
|---|---|---|
| WEBER CAPITAL MANAGEMENT LLC /ADV | $1.9M | 310,861 |
| Meros Investment Management, LP | $1.1M | 182,992 |
| ACADIAN ASSET MANAGEMENT LLC | $1.1M | 179,614 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.0M | 169,625 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $880.0K | 143,082 |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $755.3K | 122,810 |
| TWO SIGMA INVESTMENTS, LP | $704.5K | 114,545 |
| RENAISSANCE TECHNOLOGIES LLC | $610.9K | 99,327 |
| BlackRock, Inc. | $380.3K | 61,834 |
| GEODE CAPITAL MANAGEMENT, LLC | $292.5K | 47,555 |
Companies Similar to HBIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ALPHA & OMEGA SEMICONDUCTOR Ltd
SILICOM LTD.
LANTRONIX INC
STRATASYS LTD.
AIRGAIN INC
AstroNova, Inc.
CERAGON NETWORKS LTD
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put HBIO on your watchlist
Track score changes the day HARVARD BIOSCIENCE INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HBIO a good stock to buy?
13F Pro's AI-powered analysis of HARVARD BIOSCIENCE INC (HBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HBIO are available on the HBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HBIO is classified as a small company.
Which hedge funds own HBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HARVARD BIOSCIENCE INC's investment landscape.